Wed, Jan 28, 2015, 5:16 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

OncoSec Medical Incorporated Message Board

  • trysson trysson Jan 18, 2013 7:53 PM Flag

    Important to remember: ONCS is not a drug stock.

    We are not in an actual drug stock. We are in a drug-platform stock. DRUG PLATFORMS have a history of offering less reward than an actual drug. This fact should be kept in mind. However, ONCS looks like one of the best platforms ever. Am I wrong? Thoughts please.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Tryson, I have to disagree with you and agree with Twiz, that a flatform does NOT brings less value to the market as a drug. Acad vs. Clsn illustrated this that Acad upon successful phase 3 gained 150% , Clsn gained 500% I should know I owned both during that time. I truly believe as I did with Clsn back in Feb last year that ONCS will show the same massive return as CLSN has once it finish all three phase3 trials with Immunopulse. Don't gt me wrong, we will get a bump up on positive phase 2 data, but phase 3 is where the money is, let us not fool ourselves. GL!

      Sentiment: Strong Buy

      • 2 Replies to juiceupon33
      • Good posts here. Though I agree with Juiceupon: I do not think that this platform should necessarily yield less of a return than a drug. The fact is that with OncoSec there is no drug that needs to await approval by the FDA. Since it's a delivery device platform, it can be utilized with a multitude of already-existing therapies and drugs as well as be used in conjunction with yet-to-be-approved agents. It really is quite brilliant. It is an inventive and unique device and should prove itself very lucrative.

        Sentiment: Strong Buy

      • Trysson agrees with your view.

        Sentiment: Buy

    • True. Issue is later on to prove that the XXxXxXxX drug is more effective with tis platform. Snce they drugs trying are already approved that means they work... S must work better with oncs' systems, hard to prove. Anyhow, im in for the long run....just sit back and enjoy the long ride. Long, but nice at the end

      Sentiment: Buy

    • I think what makes the OMS potentially profitable is that that it is being used with FDA approved drugs already just for the expediency of accomplishing clinical trials. But the benefits of increasing uptake with reduced costs and minimal side effects can and will be applicable to any drug or future FDA approved drug, not to mention, application to others areas of cancer, be it breast or other soft tissue, pancreas, prostate etc. So anyone who can stand the 1300 volt shock at six second bursts can reap the benefits of the cure. That to me is BIG $$$

      Sentiment: Buy

    • Yes it is one of the best platforms ever, because the drug is administered directly into the tumor, and then locked into the tumor, via electroporation. Although electroporation has been around for a while, it is still relatively new in treating cancer, which is why ONCS PPS is so low. The company has only been in existence for 2 years! I don't agree that this stock has less of a chance of rewarding stockholders because it is a drug platform company, not a drug company. As more positive news from trials come out, the PPS will go up.

      Sentiment: Strong Buy

    • rbruf1959 Jan 18, 2013 8:02 PM Flag

      So we are @ .22, for what reason? Drug Platforms? Thank you. Did not know this

0.385-0.009(-2.41%)Jan 28 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.